Shares of Biomea Fusion (BMEA) gained 9.1% on Thursday after the FDA lifted the clinical hold it had earlier placed on the company's ongoing early to mid-stage studies evaluating its lead candidate, BMF-219, for treating type 2 and type 1 diabetes (T2D and T1D). The update follows a thorough review of the clinical data on the candidate, to date. Biomea's BMF-219 is an investigational novel covalent menin inhibitor that has been developed using the company's proprietary FUSION System. Recent Regulatory Updat ...